Cancer of the Liver and Biliary Tract. Adami A, Hunter D, and Trichopoulos D. Textbook of Cancer Epidemiology. Second Edition. Oxford England: Oxford University Press; 2008. 308-332.
DeVita VT, Lawrence TS, Rosenberg SA, et al. Cancer. Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1 May 2008.
El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000 Nov 27. 160(21):3227-30. [Medline].
Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997 Jun 26. 336(26):1855-9. [Medline].
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11. 340(10):745-50. [Medline].
Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007 Feb. 11(1):191-207, x-xi. [Medline].
El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18. 139(10):817-23. [Medline].
Calle EE, Teras LR, Thun MJ. Obesity and mortality. N Engl J Med. 2005 Nov 17. 353(20):2197-9. [Medline].
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005 Apr. 54(4):533-9. [Medline]. [Full Text].
Manos M,and Murphy R. Viral hepatitis registry, Kaiser Permanente Northern California, Oakland, California.Trends in the incidence and etiology of hepatocellular carcinoma in a managed care population :the roles of viral hepatitis and fatty liver disease. Hepatology. 2007. 46:400A.
American Cancer Society. Cancer Facts and Figures 2018. www.cancer.org. Available at http://cacancerjournal.org. 2018; Accessed: February 9, 2018.
Bosch FX, Ribes J, Díaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004 Nov. 127(5 Suppl 1):S5-S16. [Medline].
Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology. 1998 Oct. 28(4):1161-5. [Medline].
Kaneda K, Uenishi T, Takemura S, et al. The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol. 2012 May. 105(6):606-11. [Medline].
Arora A, Rajesh S, Bansal K, Sureka B, Patidar Y, Thapar S, et al. Cirrhosis-related musculoskeletal disease: radiological review. Br J Radiol. 2016 Oct. 89 (1066):20150450. [Medline]. [Full Text].
Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004 Oct 20. 112(1):44-50. [Medline].
Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb. 138(2):493-502. [Medline]. [Full Text].
Schottenfeld D, Fraumeni JF eds. Cancer Epidemiology and Prevention. 3rd ed. Oxford University Press; 2006.
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998 Sep. 28(3):751-5. [Medline].
Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011 May. 9(5):428-33; quiz e50. [Medline].
Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998 Jan. 27(1):273-8. [Medline].
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 4.2017. NCCN. Available at http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf. October 9, 2017; Accessed: February 8, 2018.
Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005 May 1. 23(13):2892-9. [Medline].
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005 Nov. 42(5):1208-36. [Medline].
Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol. 2007 Apr. 34(2 Suppl 1):S12-20. [Medline].
Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997 Feb. 8(2):117-36. [Medline].
Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002 Jan 15. 94(2):421-7. [Medline].
Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Apr 20. 24(12):1898-903. [Medline].
Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol. 2007. 25(suppl):962s(abstract LBA1).
Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010 Nov 17. 304(19):2154-60. [Medline].
Faivre S, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma. J Clin Oncol. 2007. 25:149s Abstract 3546.
Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005 Sep 20. 23(27):6657-63. [Medline].
Thomas M, Dutta A, Brown T, et al. A phase II open-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma. Proc Am Soc Clin Oncol. 2005. 23:4083a.
Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. Cancer. 2016 Feb 1. 122 (3):367-77. [Medline]. [Full Text].
FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. www.fda.gov. Available at https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577166.htm. September 25, 2017; Accessed: February 9, 2018.
Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001 Jul. 234(1):63-70. [Medline]. [Full Text].
Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998 Nov. 28(5):1241-6. [Medline].
Choi JG, Chung YH, Kim JA, et al. High HBV-DNA titer in surrounding liver rather than in hepatocellular carcinoma tissue predisposes to recurrence after curative surgical resection. J Clin Gastroenterol. 2012 May-Jun. 46(5):413-9. [Medline].
Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001 May. 233(5):652-9. [Medline]. [Full Text].
Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg. 1995 Jan. 169(1):28-34; discussion 34-5. [Medline].
Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991 Sep. 214(3):221-8; discussion 228-9. [Medline]. [Full Text].
Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999 Jun. 229(6):790-9; discussion 799-800. [Medline]. [Full Text].
Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000 Sep. 232(3):381-91. [Medline]. [Full Text].
Zhou Y, Zhao Y, Li B, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010 Jul 9. 10:78. [Medline]. [Full Text].
Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016 Jan 1. 370 (1):78-84. [Medline]. [Full Text].
Stuart K. Chemoembolization in the management of liver tumors. Oncologist. 2003. 8(5):425-37. [Medline].
Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010 Dec 1. 116(23):5452-60. [Medline].
Martin RC 2nd, Rustein L, Pérez Enguix D, et al. Hepatic arterial infusion of doxorubicin-loaded microsphere for treatment of hepatocellular cancer: a multi-institutional registry. J Am Coll Surg. 2011 Oct. 213(4):493-500. [Medline].
Stuart K, Stokes K, Jenkins R, Trey C, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer. 1993 Dec 1. 72(11):3202-9. [Medline].
Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998 Jun. 27(6):1578-83. [Medline].
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18. 359(9319):1734-9. [Medline].
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May. 35(5):1164-71. [Medline].
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010 Jan. 138(1):52-64. [Medline].
Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011 Feb. 140(2):497-507.e2. [Medline]. [Full Text].
Sawada N, Inoue M, Iwasaki M, et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology. 2012 Jun. 142(7):1468-75. [Medline].
Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017 Dec 1. 3 (12):1683-1691. [Medline]. [Full Text].
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. www.who.int. Available at http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1. June 2016; Accessed: February 9, 2018.
Centers for Disease Control and Prevention. Viral Hepatitis. www.CDC.gov. Available at https://www.cdc.gov/hepatitis/populations/index.htm. May 11, 2017; Accessed: February 9, 2018.
[Guideline] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar. 53 (3):1020-2. [Medline].
[Guideline] Marrero JA, Ahn J, Rajender Reddy K, Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol. 2014 Sep. 109 (9):1328-47; quiz 1348. [Medline].
[Guideline] European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr. 56 (4):908-43. [Medline].
[Guideline] Verslype C, Rosmorduc O, Rougier P, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct. 23 Suppl 7:vii41-8. [Medline].
Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999. 19(3):329-38. [Medline].